First, patients with metastatic KRAS+/TP53+ NSCLC tended to have poor outcomes with a median OS of 19.5 months (95% CI, 15.7-23.4 months), about 6.8 months shorter than those with metastatic KRAS- and/or TP53- NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.